GSK 525762

Drug Profile

GSK 525762

Alternative Names: GSK525762; GSK525762C

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Benzodiazepines; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Carcinoma; Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Nov 2016 GlaxoSmithKline plans a phase I/II trial for Breast cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in South Korea, USA, Australia, United Kingdom, Spain, Canada and France (PO, Tablet) (NCT02964507)
  • 01 May 2016 GlaxoSmithKline initiates enrolment in a phase I trial for drug-interactions in Healthy female volunteers in USA (PO) (NCT02706535)
  • 07 Mar 2016 GlaxoSmithKline plans a phase I drug-interactions trial in Healthy female volunteers in USA (PO) (NCT02706535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top